TMCINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
TREACE MEDICAL CONCEPTS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$3.88+0.01 (+0.26%)
Close on Oct 19, 2026
- Market cap
- $252.39M
- P/E (TTM)
- –
- Dividend yield
- –
TREACE MEDICAL CONCEPTS, INC. cash flow statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 79.5%
- Operating margin
- -26.2%
- Net margin
- -29.0%
- Return on equity, FY2025
- -58.9%
Financial strength
- Current ratio
- 2.90
- Debt to equity
- 0.87
- Debt to assets
- 32.7%
- Cash to current liabilities
- 30.4%
Valuation
- P/E ratio
- –
- Price to sales
- 1.23
- Price to book
- 3.73
- Dividend yield
- –